BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance
Understanding BRAF mutations in blood cancers helps researchers recognize why some leukemia patients resist treatment, sharpening focus on who needs different approaches.
This review synthesizes published evidence on BRAF mutations in CLL across chemoimmunotherapy- and targeted therapy-era cohorts, characterizing frequency (2–6%), co-mutation patterns with KRAS/NRAS/MAPK pathway, and clinical implications. BRAF is better viewed as a biological/resistance annotation than a standalone prognostic marker or routine therapeutic target, with clinical relevance greatest in Richter transformation (V600E) and genomically complex relapsed disease.
What the study was
- Study design
- Narrative/systematic review
- Population
- Adults with CLL
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Current Hematologic Malignancy Reports
Why it surfaced
Well-constructed targeted review on BRAF mutations in CLL; updates understanding of MAPK pathway resistance in the BTK/BCL2 inhibitor era. Useful reference for hematologic malignancy surveillance but no novel clinical data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.